Juan P. Wisnivesky

Juan P. Wisnivesky


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in The Lancet
Verified
Journal Article
Closed access
JWJuan P. Wisnivesky
Juan P. Wisnivesky
STSusan L Teitelbaum
Susan L Teitelbaum
ATAndrew C Todd
Andrew C Todd
PBPaolo Boffetta
Paolo Boffetta
MCMichael Crane
Michael Crane
PLPhilip J. Landrigan
Philip J. Landrigan

25 January 2008 in Cancer
Verified
Journal Article
Open access
PDF file
AGAlexander J. Greenstein
Alexander J. Greenstein
VLVirginia R. Litle
Virginia R. Litle
SSScott J. Swanson
Scott J. Swanson
CDCelia M. Divino
Celia M. Divino
SPStuart Packer
Stuart Packer
JWJuan P. Wisnivesky
Juan P. Wisnivesky
BACKGROUND: The presence of lymph node (LN) metastases in esophageal cancer has important prognostic and treatment implications. However, the optimal number of LNs that should be examined for accurate staging is controversial. In the current study, the association between survival and the number of LNs evaluated was examined in patients who underwent resection of lymph node‐negative (American Joint Committee on Cancer [AJCC] TNM stage I‐IIA) esophageal cancer.METHODS: All patients were identified who underwent surgery for lymph node‐negative esophageal cancer between 1988 and 2003 from the Surveillance, Epidemiology, and End Results cancer registry. Patients were classified into 3 groups by the number of negative LNs sampled during surgery (≤10 LNs, 11‐17 LNs, and ≥18 LNs). Esophageal cancer‐specific survival was compared among these LN groups using Kaplan‐Meier curves. Stratified and Cox regression analyses were used to evaluate the association between survival and the number of negative LNs after adjusting for potential confounders.RESULTS: A total of 972 patients were included in the study. Disease‐specific survival rates increased with a higher number of negative LNs. The 5‐year disease‐specific survival rate was 55% among patients with ≤10 negative LNs, compared with 66% and 75%, respectively, for those with 11 to 17 negative LNs and ≥18 negative LNs. The number of negative LNs was found to be significantly associated with survival in analyses stratified by tumor status. On multivariate regression controlling for age, race/ethnicity, sex, histology, tumor status, and postoperative radiotherapy, a higher number of negative LNs was found to be independently associated with higher disease‐specific survival.CONCLUSIONS: The presence of LN metastases in patients with esophageal cancer appears to have important prognostic and treatment implications. Data from the current study suggest that patients undergoing surgical resection for esophageal cancer should have at least 18 LNs removed. Cancer 2008. © 2008 American Cancer Society.

1 March 2011 in Chest
Verified
Journal Article
Closed access
PDF file
MKMax Kates
Max Kates
SSScott Swanson
Scott Swanson
JWJuan P. Wisnivesky
Juan P. Wisnivesky

1 March 2010 in Annals of Surgery
Verified
Journal Article
Closed access
JWJuan P. Wisnivesky
Juan P. Wisnivesky
CHClaudia I. Henschke
Claudia I. Henschke
SSScott Swanson
Scott Swanson
DYDavid F. Yankelevitz
David F. Yankelevitz
JZJavier Zulueta
Javier Zulueta
EHEthan A. Halm
Ethan A. Halm
Lobectomy is the standard of care for stage IA lung cancer. Some small retrospective studies have suggested similar results after limited resection for tumors ≤2 cm in size. The objective of the study was to compare survival after lobectomy and limited resection among Medicare patients with lung cancer. Using the Surveillance, Epidemiology, and End Results registry, linked to Medicare records, we identified 1165 cases of stage I lung cancer ≤2 cm in size that underwent lobectomy or limited resection (segmentectomy or wedge resection). We used logistic regression to determine propensity scores for undergoing limited resection based on the patients' preoperative characteristics. Overall and lung cancer-specific survival of patients treated with lobectomy or limited resection was compared after adjusting for their propensity score. Overall, 196 (17%) patients underwent limited resection. For the entire sample, the adjusted hazard ratio for all cause mortality (1.09; 95% confidence interval: 0.85–1.40) or lung cancer-specific death (hazard ratio: 1.39; 95% confidence interval: 0.97–2.01) for patients undergoing limited resection were not significantly different from those having lobectomy. Similarly, we found no significant differences in overall or lung cancer-specific survival for patients treated with limited resection compared with lobectomy when data was analyzed stratifying and matching patients by their propensity scores. These results suggest that survival of patients >65 years of age undergoing limited resection or lobectomy for stage IA tumors ≤2 cm appears to be similar. Although these findings should be confirmed in prospective trials, our results suggest that limited resection may be an effective therapeutic alternative for these patients.

1 September 2012 in Lung Cancer
Verified
Journal Article
Closed access
SJSirisha Jonnalagadda
Sirisha Jonnalagadda
CBCara Bergamo
Cara Bergamo
JLJenny J. Lin
Jenny J. Lin
LLLinda Lurslurchachai
Linda Lurslurchachai
MDMichael Diefenbach
Michael Diefenbach
JWJuan P. Wisnivesky
Juan P. Wisnivesky

1 September 2005 in Chest
Verified
Journal Article
Closed access
JWJuan P. Wisnivesky
Juan P. Wisnivesky
MBMarcelo Bonomi
Marcelo Bonomi
CHClaudia Henschke
Claudia Henschke
MIMichael Iannuzzi
Michael Iannuzzi
TMThomas McGinn
Thomas McGinn